Drug Approval | September 28, 2024
Zydus receives USFDA final approval for Enzalutamide Capsules, 40 mg
Enzalutamide Capsules will be produced at the Group’s manufacturing site at Moraiya, Ahmedabad
Enzalutamide Capsules will be produced at the Group’s manufacturing site at Moraiya, Ahmedabad
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
WINLEVI works differently from any other topical acne treatment
CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5%
On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors
Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI in Japan, Australia, New Zealand, Brazil, Mexico and Russia.
Darolutamide is developed jointly by Bayer and Orion Corporation
It is the first U.S. FDA approved novel topical mechanism for acne in nearly 40 years
Subscribe To Our Newsletter & Stay Updated
